估值20亿元！苏州一家创新药未来独角兽，冲刺港股IPO

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) as the sole sponsor. This marks the company's renewed attempt after a previous application expired in February 2026 [4][20]. Company Overview - Tianchen Biopharmaceuticals was established in October 2020 in Suzhou, Jiangsu Province. The company focuses on the development of innovative drugs, particularly biopharmaceuticals targeting allergic and autoimmune diseases. It has developed a comprehensive pipeline of biological products across various medical fields [7]. - The company has been recognized as a potential unicorn by national authorities in 2025 [7]. Key Products - The core product, LP-003, is an anti-IgE antibody designed to block free IgE in blood and tissues, aimed at treating allergic diseases such as seasonal allergic rhinitis, chronic spontaneous urticaria, and allergic asthma [8]. - Another major product, LP-005, is a dual-function antibody targeting C5 and C3b complement, primarily for treating paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated kidney diseases. Initial clinical studies have shown promising safety and efficacy [9]. Market Potential - The market for allergic disease medications in China is projected to grow from $8.1 billion in 2024 to $22.9 billion by 2030, with the market share of biopharmaceuticals expected to increase from 19.8% to 54.1% [9]. Development Milestones - Key events in the company's development include: - October 2020: Establishment of Tianchen Biopharmaceuticals [10]. - March 2022: LP-003 received clinical trial approval from the National Medical Products Administration (NMPA) [10]. - April 2023: LP-005's clinical trial application was accepted by the NMPA [12]. - February 2024: Positive results from the Phase II clinical trial of LP-003 for allergic rhinitis were announced [14]. Founders' Background - The company was co-founded by Dr. Liu Heng and Dr. Sun Naichao, both of whom have extensive experience in biopharmaceutical research and development [24][26].